Pathologic SFK activity may contribute to BCR–ABL-independent imatinib resistance in CML (Donato et al. 2003; Pene-Dumitrescu and Smithall 2010). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.